Novavax, Inc. (NVAX)

14,40 -0,65 (-4,32%) Börsenschluss: 04:00PM EDT

Novavax, Inc.

700 Quince Orchard Road
Gaithersburg, MD 20878
United States
240 268 2000
https://www.novavax.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 1.543

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. John Charles Jacobs M.B.A.	President, CEO & Director	1,33M	N/A	1967
Mr. John Joseph Trizzino B.S., M.B.A.	President & COO	670,55k	N/A	1960
Mr. James Patrick Kelly C.F.A.	Executive VP, CFO & Treasurer	716,17k	N/A	1966
Mr. Mark Casey	Executive VP, Chief Legal Officer & Corporate Secretary	137,36k	N/A	1963
Mr. Stanley Charles Erck	Advisor	1,41M	N/A	1948
Dr. Filip Dubovsky FAAP, M.D., M.P.H.	President of Research & Development	858,77k	N/A	1965
Mr. Richard P. Crowley	Executive VP & COO	N/A	N/A	1957
Mr. Troy Morgan Esq., J.D.	Senior VP & Chief Compliance Officer	N/A	N/A	1971
Ms. Erika S. Trahan	Associate Director of Investor & Public Relations	N/A	N/A	N/A
Mr. Ian J. Watkins	Executive VP & Chief Human Resources Officer	N/A	N/A	1963

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Corporate Governance

Novavax, Inc.s ISS Governance QualityScore, Stand 1. Juni 2024, lautet 5. Die grundlegenden Scores sind Audit: 7, Vorstand: 3, Shareholderrechte: 5, Kompensation: 6.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.